Liminatus Pharma, Inc. Class A Common Stock
LIMN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.068 | 0.005 | -2.55 | -0.12 |
| % Growth | -1,477.6% | 100.2% | -2,025% | – |
| Operating Cash Flow | -$0 | -$0 | $0 | -$0 |
| Capital Expenditures | -$0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | $0 | -$0 |